
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2879158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 61.e21-61.e28.	0.8	2
2	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
3	Innovative systemic therapies for penile cancer. Current Opinion in Urology, 2022, 32, 8-16.	0.9	8
4	<i>FGFR2/3 g</i> enomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass, 2022, 3, 169-172.	0.7	7
5	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British Journal of Cancer, 2022, 126, 430-439.	2.9	15
6	Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. European Urology Oncology, 2022, 5, 719-721.	2.6	1
7	Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groups. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
8	Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist, 2022, 27, 432-e452.	1.9	2
9	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. European Journal of Cancer, 2022, 163, 55-65.	1.3	5
10	Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma. Oncologist, 2022, 27, e406-e409.	1.9	4
11	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. European Urology, 2022, 81, 466-473.	0.9	12
12	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 532-532.	0.8	0
13	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
14	Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) to predict outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2022, 40, 449-449.	0.8	1
15	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2022, 40, 485-485.	0.8	0
16	Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy Journal of Clinical Oncology, 2022, 40, 558-558.	0.8	0
17	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy Journal of Clinical Oncology, 2022, 40, 528-528.	0.8	7
18	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States Journal of Clinical Oncology, 2022, 40, TPS578-TPS578.	0.8	1

#	Article	IF	CITATIONS
19	Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC) Journal of Clinical Oncology, 2022, 40, 511-511.	0.8	0
20	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial Journal of Clinical Oncology, 2022, 40, TPS588-TPS588.	0.8	3
21	Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC) Journal of Clinical Oncology, 2022, 40, 565-565.	0.8	1
22	Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011) Journal of Clinical Oncology, 2022, 40, TPS591-TPS591.	0.8	1
23	A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 518-518.	0.8	0
24	Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs) Journal of Clinical Oncology, 2022, 40, TPS595-TPS595.	0.8	2
25	Association of changes in albumin levels with survival and toxicities in patients (pts) with metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV) Journal of Clinical Oncology, 2022, 40, 481-481.	0.8	6
26	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI) Journal of Clinical Oncology, 2022, 40, 549-549.	0.8	1
27	Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3) Journal of Clinical Oncology, 2022, 40, TPS585-TPS585.	0.8	2
28	Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study Journal of Clinical Oncology, 2022, 40, 501-501.	0.8	9
29	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas. Journal of Clinical Oncology, 2022, 40, 1275-1280.	0.8	6
30	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers, 2022, 14, 1795.	1.7	15
31	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	0.9	4
32	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer, 2022, 128, 1194-1205.	2.0	26
33	A global approach to improving penile cancer care. Nature Reviews Urology, 2022, 19, 231-239.	1.9	28
34	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. British Journal of Cancer, 2022, 126, 797-803.	2.9	17
35	Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, 22, 449-455.	1.1	9
36	Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clinical Genitourinary Cancer, 2022, 20, 301-306.	0.9	7

#	Article	IF	CITATIONS
37	Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. American Journal of Medicine, 2022, 135, 984-992.e6.	0.6	5
38	Clinical outcomes and patterns of populationâ€based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. Cancer Medicine, 2022, 11, 4273-4282.	1.3	4
39	TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3β/β-catenin signalling. Nature Communications, 2022, 13, 2792.	5.8	15
40	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology, 2022, 18, 2599-2614.	1.1	10
41	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e440-e452.	0.9	10
42	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncology, 2022, 18, 2771-2781.	1.1	2
43	Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4516-4516.	0.8	13
44	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer, 2021, 127, 840-849.	2.0	51
45	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Critical Reviews in Oncology/Hematology, 2021, 157, 103198.	2.0	35
46	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. Expert Review of Anticancer Therapy, 2021, 21, 299-313.	1.1	6
47	Considerations in prescribing pharmacotherapy for localized and metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-4.	0.9	5
48	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. Journal of Urology, 2021, 205, 414-419.	0.2	3
49	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18
50	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study Journal of Clinical Oncology, 2021, 39, 443-443.	0.8	4
51	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC) Journal of Clinical Oncology, 2021, 39, 445-445.	0.8	2
52	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2021, 39, 472-472.	0.8	4
53	<i>CDKN2A</i> alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC) Journal of Clinical Oncology, 2021, 39, 475-475.	0.8	4
54	Association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) in patients (pts) with metastatic urothelial carcinoma (mUC) during checkpoint immunotherapy Journal of Clinical Oncology, 2021, 39, 489-489.	0.8	0

#	Article	IF	CITATIONS
55	Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2021, 39, 393-393.	0.8	8
56	Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy Journal of Clinical Oncology, 2021, 39, 414-414.	0.8	1
57	Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2021, 39, 453-453.	0.8	1
58	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2021, 39, 354-354.	0.8	0
59	Genomic landscape of variant urinary tumor histologies Journal of Clinical Oncology, 2021, 39, 467-467.	0.8	4
60	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Reports, 2021, 34, 108926.	2.9	16
61	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 1125-1135.	13.9	473
62	New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2375-2377.	3.2	4
63	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	0.8	65
64	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 540-546.	0.9	10
65	Optimal pathological response after neoadjuvant chemotherapy for muscleâ€invasive bladder cancer: results from a global, multicentre collaboration. BJU International, 2021, 128, 607-614.	1.3	10
66	Disparities in reporting and representation of women, older adults and racial minorities in immune checkpoint inhibitor (ICI) clinical trials Journal of Clinical Oncology, 2021, 39, 6549-6549.	0.8	1
67	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers Journal of Clinical Oncology, 2021, 39, 10536-10536.	0.8	0
68	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy Journal of Clinical Oncology, 2021, 39, 4539-4539.	0.8	9
69	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. Bladder Cancer, 2021, 7, 143-148.	0.2	2
70	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC) Journal of Clinical Oncology, 2021, 39, e16515-e16515.	0.8	1
71	Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad) Journal of Clinical Oncology, 2021, 39, 5036-5036.	0.8	1
72	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics, 2021, 20, 1454-1461.	1.9	6

#	Article	IF	CITATIONS
73	Preclinical Models for Bladder Cancer Research. Hematology/Oncology Clinics of North America, 2021, 35, 613-632.	0.9	7
74	Management of Bladder Cancer: The First Inning of a New Era of Rapid Advances. Hematology/Oncology Clinics of North America, 2021, 35, xiii-xx.	0.9	0
75	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
76	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	3.2	51
77	Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncology, 2021, 17, 2545-2558.	1.1	39
78	Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical Genitourinary Cancer, 2021, , .	0.9	3
79	Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology, 2021, 154, 208-214.	0.5	3
80	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal of Clinical Investigation, 2021, 131, .	3.9	17
81	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical Genitourinary Cancer, 2021, 19, 425-433.	0.9	15
82	Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 733.e1-733.e10.	0.8	5
83	Management of Metastatic Penile Cancer. , 2021, , 125-132.		1
84	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. European Urology Focus, 2021, 7, 1339-1346.	1.6	58
85	Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. , 2021, 9, e002917.		27
86	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology, 2020, 38, 143-150.	1.2	49
87	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. European Urology Oncology, 2020, 3, 540-543.	2.6	13
88	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. European Urology Oncology, 2020, 3, 680-686.	2.6	14
89	Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. European Urology Focus, 2020, 6, 14-16.	1.6	9
90	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European Urology Oncology, 2020, 3, 695-699.	2.6	30

#	Article	IF	CITATIONS
91	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e266-e276.	0.9	12
92	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncology, 2020, 16, 4359-4368.	1.1	61
93	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	2.9	59
94	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genetics in Medicine, 2020, 22, 709-718.	1.1	44
95	Impact of performance status on treatment outcomes: A realâ€world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	2.0	70
96	PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. Matrix Biology, 2020, 89, 43-58.	1.5	17
97	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics, 2020, 23, 967-977.	1.0	13
98	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nature Medicine, 2020, 26, 1041-1043.	15.2	161
99	Neoadjuvant therapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2020, 20, 603-614.	1.1	11
100	Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2305-2317.	2.0	11
101	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival. Radiology, 2020, 295, 572-580.	3.6	7
102	A CD24â€p53 axis contributes to African American prostate cancer disparities. Prostate, 2020, 80, 609-618.	1.2	11
103	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	0.8	42
104	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene, 2020, 39, 4077-4091.	2.6	19
105	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. , 2020, 8, e000371.		14
106	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
107	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	0.9	7
108	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 151, 102992.	2.0	28

#	Article	IF	CITATIONS
109	The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing. Cancer Treatment and Research Communications, 2020, 23, 100165.	0.7	9
110	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2020, 203, 690-698.	0.2	76
111	Systematic Review and Meta-Analysis—Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. Journal of Urology, 2020, 203, 1147-1155.	0.2	39
112	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.2	32
113	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. Journal of Urology, 2020, 204, 1173-1179.	0.2	47
114	Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers Journal of Clinical Oncology, 2020, 38, 5018-5018.	0.8	9
115	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <i>FGFR3</i> alterations Journal of Clinical Oncology, 2020, 38, TPS5095-TPS5095.	0.8	9
116	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy Journal of Clinical Oncology, 2020, 38, 439-439.	0.8	101
117	Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2020, 38, 473-473.	0.8	2
118	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2 Journal of Clinical Oncology, 2020, 38, 507-507.	0.8	12
119	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2020, 38, e19390-e19390.	0.8	0
120	Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo) Journal of Clinical Oncology, 2020, 38, 5540-5540.	0.8	8
121	A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2020, 38, TPS5091-TPS5091.	0.8	1
122	Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2020, 38, e17044-e17044.	0.8	0
123	Detection of urothelial carcinoma using plasma cell-free methylated DNA Journal of Clinical Oncology, 2020, 38, 5046-5046.	0.8	0
124	Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile Journal of Clinical Oncology, 2020, 38, e17596-e17596.	0.8	0
125	Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer Journal of Clinical Oncology, 2020, 38, e17597-e17597.	0.8	1
126	Dissecting outcomes of patients (pts) with <ypt2n0 (nac)="" after="" chemotherapy="" disease="" for<br="" neoadjuvant="">muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration Journal of Clinical Oncology, 2020, 38, 5043-5043.</ypt2n0>	0.8	0

#	Article	IF	CITATIONS
127	Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need Journal of Clinical Oncology, 2020, 38, 5048-5048.	0.8	0
128	Reply by Authors. Journal of Urology, 2020, 203, 1155-1155.	0.2	0
129	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. Molecular Cancer Research, 2019, 17, 84-96.	1.5	37
130	A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, S254-S256.	0.6	0
131	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. Translational Oncology, 2019, 12, 1416-1424.	1.7	21
132	Advanced urothelial cancer: a radiology update. Abdominal Radiology, 2019, 44, 3858-3873.	1.0	5
133	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 821-826.	1.9	24
134	Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 284-300.	1.8	14
135	Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. American Journal of Roentgenology, 2019, 212, 1060-1069.	1.0	12
136	Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Letters, 2019, 454, 1-13.	3.2	20
137	Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. Cancer Research, 2019, 79, 1413-1425.	0.4	27
138	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Current Treatment Options in Oncology, 2019, 20, 12.	1.3	20
139	Capturing recurrence in urothelial carcinoma: "more than meets the eye― Translational Andrology and Urology, 2019, 8, S524-S527.	0.6	0
140	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. Oncology Reviews, 2019, 13, 455.	0.8	12
141	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	3.2	102
142	Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy, 2019, 20, 201-208.	0.9	12
143	Circulating tumor DNA alterations in patients with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 1459-1469.	2.0	38
144	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56

#	Article	IF	CITATIONS
145	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 2019, 125, 533-540.	2.0	38
146	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
147	Examining the relationship between complications and perioperative mortality following radical cystectomy: a populationâ€based analysis. BJU International, 2019, 124, 40-46.	1.3	17
148	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World Journal of Urology, 2019, 37, 95-105.	1.2	19
149	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333
150	Taxane-based Combination Therapies for Metastatic Prostate Cancer. European Urology Focus, 2019, 5, 369-380.	1.6	23
151	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors Journal of Clinical Oncology, 2019, 37, 4552-4552.	0.8	3
152	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2019, 37, 432-432.	0.8	1
153	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma Journal of Clinical Oncology, 2019, 37, 435-435.	0.8	9
154	Defining "platinum-ineligible―patients with metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2019, 37, 451-451.	0.8	24
155	Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs) Journal of Clinical Oncology, 2019, 37, 479-479.	0.8	3
156	PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region Journal of Clinical Oncology, 2019, 37, 515-515.	0.8	2
157	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD) Journal of Clinical Oncology, 2019, 37, 653-653.	0.8	4
158	EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) Journal of Clinical Oncology, 2019, 37, TPS497-TPS497.	0.8	12
159	Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation Journal of Clinical Oncology, 2019, 37, TPS504-TPS504.	0.8	16
160	Predictive role of CT texture analysis in patients with metastatic urothelial cancer treated with PD-1/PD-L1 inhibitors Journal of Clinical Oncology, 2019, 37, 424-424.	0.8	0
161	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors Journal of Clinical Oncology, 2019, 37, 476-476.	0.8	0
162	Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2019, 37, 401-401.	0.8	1

#	Article	IF	CITATIONS
163	A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC) Journal of Clinical Oncology, 2019, 37, TPS494-TPS494.	0.8	0
164	Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) Journal of Clinical Oncology, 2019, 37, 226-226.	0.8	0
165	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2019, 37, 454-454.	0.8	0
166	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	2.0	79
167	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. Urologic Clinics of North America, 2018, 45, 143-154.	0.8	17
168	Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?. European Urology, 2018, 74, 63-65.	0.9	4
169	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
170	Taxane chemotherapy vs antiandrogen agents as firstâ€line therapy for metastatic castrationâ€resistant prostate cancer. BJU International, 2018, 121, 871-879.	1.3	23
171	Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. Current Treatment Options in Oncology, 2018, 19, 2.	1.3	8
172	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. Clinical Genitourinary Cancer, 2018, 16, e277-e287.	0.9	4
173	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	0.9	99
174	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 163-170.	1.9	5
175	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	0.9	14
176	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. European Urology Focus, 2018, 4, 733-736.	1.6	18
177	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus, 2018, 4, 874-879.	1.6	30
178	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus, 2018, 4, 937-945.	1.6	7
179	Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum. European Urology, 2018, 73, 153-155.	0.9	1
180	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Molecular Cancer Research, 2018, 16, 1125-1137.	1.5	51

#	Article	IF	CITATIONS
181	Promising immunotherapy for prostate cancer. Expert Opinion on Biological Therapy, 2018, 18, 109-120.	1.4	5
182	Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. Journal of Clinical Oncology, 2018, 36, 3189-3191.	0.8	11
183	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	0.8	79
184	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2
185	Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion–Positive Metastatic Urothelial Carcinoma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	0
186	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian Journal of Andrology, 2018, 20, 230.	0.8	9
187	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. Journal of Urology, 2018, 200, 1207-1214.	0.2	26
188	Immunotherapy for advanced penile cancer — rationale and potential. Nature Reviews Urology, 2018, 15, 721-723.	1.9	14
189	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.	2.9	34
190	Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology, 2018, 1, 190-198.	2.6	26
191	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. Bladder Cancer, 2018, 4, 227-238.	0.2	55
192	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 2018, 9, 19861-19873.	0.8	37
193	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia, 2018, 20, 894-904.	2.3	50
194	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. Prostate Cancer and Prostatic Diseases, 2018, 21, 419-430.	2.0	3
195	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
196	JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncology, The, 2018, 19, 5-7.	5.1	2
197	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) Journal of Clinical Oncology, 2018, 36, TPS4588-TPS4588.	0.8	6
198	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP) Journal of Clinical Oncology, 2018, 36, LBA5009-LBA5009.	0.8	24

#	Article	IF	CITATIONS
199	Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials Journal of Clinical Oncology, 2018, 36, 225-225.	0.8	2
200	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab Journal of Clinical Oncology, 2018, 36, 413-413.	0.8	10
201	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma Journal of Clinical Oncology, 2018, 36, 451-451.	0.8	1
202	A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A Journal of Clinical Oncology, 2018, 36, TPS538-TPS538.	0.8	3
203	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) Journal of Clinical Oncology, 2018, 36, TPS539-TPS539.	0.8	24
204	Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial Journal of Clinical Oncology, 2018, 36, 190-190.	0.8	0
205	C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy Journal of Clinical Oncology, 2018, 36, 436-436.	0.8	Ο
206	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients Journal of Clinical Oncology, 2018, 36, 314-314.	0.8	0
207	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T Journal of Clinical Oncology, 2018, 36, e17041-e17041.	0.8	ο
208	Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 53-59.	0.9	1
209	Endostatin inhibits androgenâ€independent prostate cancer growth by suppressing nuclear receptorâ€mediated oxidative stress. FASEB Journal, 2017, 31, 1608-1619.	0.2	11
210	PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1073-1074.	13.9	46
211	Drug development in prostate cancer: time to embrace RECIST?. Lancet Oncology, The, 2017, 18, 419-421.	5.1	5
212	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
213	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	0.9	1
214	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	0.9	108
215	Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy, 2017, 9, 463-466.	1.0	2
216	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Medicine (United States), 2017, 96, e6817.	0.4	4

#	Article	IF	CITATIONS
217	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer, 2017, 15, 635-641.	0.9	5
218	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 534-539.	0.9	3
219	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunology, Immunotherapy, 2017, 66, 1345-1357.	2.0	22
220	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, 548-555.e3.	0.9	37
221	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology, 2017, 71, 281-289.	0.9	56
222	Update of systemic immunotherapy for advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 678-686.	0.8	12
223	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1240-1267.	2.3	220
224	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	2.3	443
225	The biology of prostate cancer metastases. Current Opinion in Urology, 2017, 27, 542-546.	0.9	8
226	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. Expert Opinion on Emerging Drugs, 2017, 22, 347-355.	1.0	0
227	Editorial Comment. Urology, 2017, 108, 140-141.	0.5	0
228	Editorial comment. Urology, 2017, 106, 124.	0.5	0
229	Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability. European Urology, 2017, 71, 172-173.	0.9	4
230	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU International, 2017, 119, 579-584.	1.3	16
231	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. Clinical Genitourinary Cancer, 2017, 15, 213-220.e5.	0.9	27
232	<i>CD24</i> is a genetic modifier for risk and progression of prostate cancer. Molecular Carcinogenesis, 2017, 56, 641-650.	1.3	14
233	Efficacy and Safety of Cemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2017, 15, 23-30.e2.	0.9	50
234	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68

#	Article	IF	CITATIONS
235	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Journal of Cancer, 2017, 8, 2663-2668.	1.2	5
236	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-NaÃ⁻ve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	0.8	73
237	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing Journal of Clinical Oncology, 2017, 35, 1514-1514.	0.8	3
238	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape Journal of Clinical Oncology, 2017, 35, 4534-4534.	0.8	2
239	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden Journal of Clinical Oncology, 2017, 35, 4582-4582.	0.8	2
240	Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy Journal of Clinical Oncology, 2017, 35, 149-149.	0.8	8
241	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival Journal of Clinical Oncology, 2017, 35, 346-346.	0.8	2
242	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. Oncotarget, 2017, 8, 21710-21718.	0.8	14
243	Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget, 2017, 8, 29220-29232.	0.8	10
244	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide Journal of Clinical Oncology, 2017, 35, e16503-e16503.	0.8	0
245	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial Journal of Clinical Oncology, 2017, 35, 5022-5022.	0.8	ο
246	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials Journal of Clinical Oncology, 2017, 35, e16012-e16012.	0.8	0
247	Impact of perioperative chemotherapy and radiation for locally advanced penile squamous cell carcinoma (PSCC) Journal of Clinical Oncology, 2017, 35, 4589-4589.	0.8	Ο
248	Abstract 1263: Andrographolide inhibits prostate cancer by suppressing cytokine involved in promoting epithelial to mesenchymal transition. , 2017, , .		0
249	Abstract 2328: Race specific hyper-activation of CCR9-mediated survival signals and its impact on efficacy of docetaxel in prostate cancer. , 2017, , .		0
250	Abstract 5252: Quercetin inhibits prostate cancer by modulating ROS and key regulators of apoptosis and cell survival. , 2017, , .		0
251	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 341-349.	0.2	7
252	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or) Tj ETQq0 (	) 0 rgBT / 1.6	Overlock 10 Tr 23

202

487.

#	Article	IF	CITATIONS
253	Combination therapy for metastatic renal cell carcinoma. Annals of Translational Medicine, 2016, 4, 100-100.	0.7	22
254	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 497-506.	0.6	15
255	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	2.3	93
256	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
257	Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clinical Genitourinary Cancer, 2016, 14, 331-340.	0.9	12
258	Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. European Urology, 2016, 70, 203.	0.9	1
259	Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle, 2016, 15, 819-826.	1.3	33
260	Angiogenesis as a therapeutic target in urothelial carcinoma. Nature Reviews Urology, 2016, 13, 306-307.	1.9	17
261	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United) Tj ETQq1 1 (	).784314 ı 0.4	gBT /Overloc
262	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1113-1120.	1.5	5
263	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. Lancet Oncology, The, 2016, 17, 1477-1478.	5.1	2
264	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opinion on Biological Therapy, 2016, 16, 1387-1401.	1.4	22
265	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Human Vaccines and Immunotherapeutics, 2016, 12, 2997-3004.	1.4	12
266	Reply to L.J. Eapen et al. Journal of Clinical Oncology, 2016, 34, 3228-3229.	0.8	0
267	Emerging Systemic Therapies for the Management of Penile Cancer. Urologic Clinics of North America, 2016, 43, 481-491.	0.8	12
268	Circulating Biomarkers in Bladder Cancer. Bladder Cancer, 2016, 2, 369-379.	0.2	25
269	Immunotherapy for Renal Cancer: Sequencing and Combinations. European Urology Focus, 2016, 2, 582-588.	1.6	5
270	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34535.	0.6	34

#	Article	IF	CITATIONS
271	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British Journal of Cancer, 2016, 115, 12-19.	2.9	9
272	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Journal of Urology, 2016, 196, 95-100.	0.2	70
273	Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. Journal of Clinical Oncology, 2016, 34, 780-785.	0.8	8
274	Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. European Urology, 2016, 70, 42-44.	0.9	0
275	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 4.e11-4.e17.	0.8	14
276	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Critical Reviews in Oncology/Hematology, 2016, 98, 122-136.	2.0	24
277	Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?. European Urology, 2016, 69, 574-575.	0.9	0
278	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology, 2016, 69, 634-641.	0.9	53
279	The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer. European Urology, 2016, 69, 863-865.	0.9	0
280	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 624-633.	0.9	25
281	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.2	54
282	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. European Urology, 2016, 69, 980-983.	0.9	12
283	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44. European Urology, 2016, 69, 644-645.	0.9	0
284	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB) Journal of Clinical Oncology, 2016, 34, 4524-4524.	0.8	6
285	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder Journal of Clinical Oncology, 2016, 34, 4528-4528.	0.8	4
286	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2016, 34, 4532-4532.	0.8	9
287	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB) Journal of Clinical Oncology, 2016, 34, 4540-4540.	0.8	2
288	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 5007-5007.	0.8	4

#	Article	IF	CITATIONS
289	Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa) Journal of Clinical Oncology, 2016, 34, 5035-5035.	0.8	1
290	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2016, 34, TPS4576-TPS4576.	0.8	11
291	Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 191-191.	0.8	1
292	The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 215-215.	0.8	1
293	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer Journal of Clinical Oncology, 2016, 34, 357-357.	0.8	21
294	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma Journal of Clinical Oncology, 2016, 34, 358-358.	0.8	4
295	Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors Journal of Clinical Oncology, 2016, 34, 385-385.	0.8	1
296	Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2016, 34, 451-451.	0.8	7
297	Whole-exome sequencing (WES) of penile squamous cell carcinoma (PSCC) to identify multiple recurrent mutations Journal of Clinical Oncology, 2016, 34, 484-484.	0.8	1
298	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. PLoS ONE, 2016, 11, e0160924.	1.1	20
299	Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials Journal of Clinical Oncology, 2016, 34, 213-213.	0.8	0
300	Pan-HER tyrosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts) Journal of Clinical Oncology, 2016, 34, 483-483.	0.8	0
301	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2016, 34, 386-386.	0.8	Ο
302	Association of a combined panel of tumor infiltrating lymphocytes, plasma cells, and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery Journal of Clinical Oncology, 2016, 34, 502-502.	0.8	0
303	Abstract B12: Macrophage inhibitory cytokine-1 as a potential biomarker for racial disparity in prostate cancer. , 2016, , .		Ο
304	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT) Journal of Clinical Oncology, 2016, 34, e16026-e16026.	0.8	0
305	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421 Journal of Clinical Oncology, 2016, 34, 5079-5079.	0.8	0
306	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients Journal of Clinical Oncology, 2016, 34, 3068-3068.	0.8	0

#	Article	IF	CITATIONS
307	Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets Journal of Clinical Oncology, 2016, 34, e16014-e16014.	0.8	0
308	Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma Journal of Clinical Oncology, 2016, 34, e16579-e16579.	0.8	0
309	Abstract 1011: Endostatin regulates androgen receptor-mediated metabolic and oxido-reductive pathways in prostate cancer cells. , 2016, , .		0
310	Abstract 5254: Andrographolide prevents prostate cancer by targeting CXCR3/CXCR7 and regulators of cell cycle. , 2016, , .		0
311	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	0.4	43
312	Cabazitaxel for the therapy of metastatic castrationâ€resistant prostate cancer in the aftermath of the <scp>CHAARTED</scp> trial. BJU International, 2015, 116, 839-840.	1.3	0
313	Third-Line Chemotherapy for Metastatic Urothelial Cancer. Medicine (United States), 2015, 94, e2297.	0.4	16
314	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLoS ONE, 2015, 10, e0139267.	1.1	34
315	Docetaxel for the treatment of bladder cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1657-1664.	1.9	13
316	Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial. European Urology, 2015, 68, 1098-1099.	0.9	0
317	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 93, 257-276.	2.0	37
318	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy forÂUrothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 185-192.	0.9	2
319	Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clinical Genitourinary Cancer, 2015, 13, 309-318.	0.9	43
320	Corticosteroids in the Management of Prostate Cancer: A Critical Review. Current Treatment Options in Oncology, 2015, 16, 6.	1.3	27
321	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 2015, 13, 178-184.	0.9	15
322	Editorial Comment. Journal of Urology, 2015, 194, 329-330.	0.2	0
323	Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?. Oncologist, 2015, 20, 461-463.	1.9	4
324	Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2015, 13, 469-475.	0.9	7

#	Article	IF	CITATIONS
325	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 95, 251-263.	2.0	8
326	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European Urology, 2015, 68, 850-858.	0.9	74
327	Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU International, 2015, 115, 854-855.	1.3	4
328	Danger on a Half Shell: Vibrio vulnificus Septicemia. American Journal of Medicine, 2015, 128, 475-476.	0.6	5
329	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2015, 94, 136-145.	2.0	33
330	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2015, 94, 228-237.	2.0	111
331	Cytotoxic chemotherapy in the contemporary management of metastatic castrationâ€resistant prostate cancer ( <scp>mCRPC</scp> ). BJU International, 2015, 116, 17-29.	1.3	19
332	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 3420-3427.	3.2	31
333	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2015, 13, e217-e221.	0.9	13
334	Incomplete Cross-Resistance Between Taxanes forÂAdvanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clinical Genitourinary Cancer, 2015, 13, 250-256.	0.9	5
335	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. Clinical Genitourinary Cancer, 2015, 13, 171-177.e1.	0.9	9
336	The expanding role of chemotherapy in prostate cancer. Future Oncology, 2015, 11, 2637-2640.	1.1	1
337	Emerging agents for the therapy of advanced prostate cancer. Future Oncology, 2015, 11, 2775-2787.	1.1	10
338	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncology, 2015, 11, 3091-3098.	1.1	17
339	Future Directions and Targeted Therapies in Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 361-376.	0.9	22
340	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer Journal of Clinical Oncology, 2015, 33, TPS4571-TPS4571.	0.8	7
341	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy Journal of Clinical Oncology, 2015, 33, TPS4572-TPS4572.	0.8	9
342	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes Journal of Clinical Oncology, 2015, 33, TPS4575-TPS4575.	0.8	4

#	Article	IF	CITATIONS
343	Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients Journal of Clinical Oncology, 2015, 33, 305-305.	0.8	3
344	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma Journal of Clinical Oncology, 2015, 33, 311-311.	0.8	1
345	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma Journal of Clinical Oncology, 2015, 33, 426-426.	0.8	7
346	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy Journal of Clinical Oncology, 2015, 33, 335-335.	0.8	0
347	Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets Journal of Clinical Oncology, 2015, 33, 389-389.	0.8	1
348	Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, 186-186.	0.8	0
349	Kinase gene expression profiling of metastatic tumor tissue to prioritize therapeutic targets in clear cell renal cell carcinoma Journal of Clinical Oncology, 2015, 33, 476-476.	0.8	0
350	Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial Journal of Clinical Oncology, 2015, 33, 475-475.	0.8	0
351	Impact of obesity in patients with metastatic urothelial carcinoma Journal of Clinical Oncology, 2015, 33, 346-346.	0.8	0
352	Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction Journal of Clinical Oncology, 2015, 33, 321-321.	0.8	0
353	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2015, 33, 4527-4527.	0.8	0
354	Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, 5057-5057.	0.8	0
355	Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, e16095-e16095.	0.8	0
356	Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy Journal of Clinical Oncology, 2015, 33, e15633-e15633.	0.8	0
357	Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2015, 33, e16030-e16030.	0.8	0
358	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials Journal of Clinical Oncology, 2015, 33, e15583-e15583.	0.8	0
359	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY Journal of Clinical Oncology, 2015, 33, 5031-5031.	0.8	1
360	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis Journal of Clinical Oncology, 2015, 33, e15527-e15527.	0.8	0

#	Article	IF	CITATIONS
361	Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis Journal of Clinical Oncology, 2015, 33, e15526-e15526.	0.8	0
362	Abstract 4107: CCR9/CCL25 mediates epithelial-mesenchymal transition in prostate cancer. , 2015, , .		0
363	Abstract 5362: Andrographolide inhibits prostate cancer by modulating chemokine and cytokines. , 2015, , .		0
364	Abstract 5531: Combination drug delivery using PBM nanoparticle to improve prostate cancer therapy. , 2015, , .		0
365	Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. Future Oncology, 2014, 10, 1819-1826.	1.1	10
366	An openâ€label, singleâ€arm, phase 2 trial of the poloâ€like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer, 2014, 120, 976-982.	2.0	75
367	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. BJU International, 2014, 113, E137-43.	1.3	31
368	Radiographic progression by Prostate Cancer Working Group ( <scp>PCWG</scp> )â€2 criteria as an intermediate endpoint for drug development in metastatic castrationâ€resistant prostate cancer. BJU International, 2014, 114, E25-E31.	1.3	39
369	Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Oncology Research and Treatment, 2014, 37, 772-776.	0.8	23
370	Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anti-Cancer Drugs, 2014, 25, 878-886.	0.7	17
371	Update in Systemic Therapy of Urologic Malignancies. Postgraduate Medicine, 2014, 126, 44-54.	0.9	6
372	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 501-508.	0.8	31
373	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 440-446.	0.9	29
374	Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer. Clinical Genitourinary Cancer, 2014, 12, 71-73.	0.9	41
375	Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews, 2014, 40, 190-196.	3.4	67
376	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology, 2014, 9, 195-204.	1.7	20
377	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 48.e1-48.e8.	0.8	10
378	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 2014, 32, 235-242.	1.2	21

#	Article	IF	CITATIONS
379	Precision medicine for metastatic renal cell carcinoma LDisclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau Urologic Oncology: Seminars and Original Investigations, 2014,	0.8	16
380	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 305-315.	1.9	20
381	The hypothalamic–pituitary–gonadal axis and prostate cancer: implications for androgen deprivation therapy. World Journal of Urology, 2014, 32, 669-676.	1.2	36
382	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 433-439.	0.9	24
383	The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. European Urology, 2014, 65, 3-6.	0.9	142
384	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, 317-324.	0.9	60
385	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2014, 90, 253-261.	2.0	13
386	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e15-30.e21.	0.8	14
387	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	0.9	27
388	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju124.	3.0	2,202
389	Patient Eligibility and Trial Design for the Salvage Therapy ofÂAdvanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 395-398.	0.9	12
390	Do the Sites of Metastases Provide Additional Information Regarding Prognosis and Biology in Renal Cell Carcinoma?. European Urology, 2014, 65, 585-586.	0.9	3
391	Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 36.e27-36.e34.	0.8	13
392	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
393	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer Journal of Clinical Oncology, 2014, 32, TPS4593-TPS4593.	0.8	3
394	Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2014, 32, 223-223.	0.8	1
395	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2014, 32, 324-324.	0.8	4
396	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy Journal of Clinical Oncology, 2014, 32, 336-336.	0.8	1

#	Article	IF	CITATIONS
397	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy Journal of Clinical Oncology, 2014, 32, 353-353.	0.8	2
398	Distribution and geographic accessibility of prostate cancer clinical trials in the United States Journal of Clinical Oncology, 2014, 32, 59-59.	0.8	1
399	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma Journal of Clinical Oncology, 2014, 32, 341-341.	0.8	0
400	Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2014, 32, 28-28.	0.8	0
401	Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis Journal of Clinical Oncology, 2014, 32, 43-43.	0.8	0
402	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC) Journal of Clinical Oncology, 2014, 32, 383-383.	0.8	1
403	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC) Journal of Clinical Oncology, 2014, 32, 409-409.	0.8	2
404	External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2014, 32, 4542-4542.	0.8	0
405	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study Journal of Clinical Oncology, 2014, 32, e15616-e15616.	0.8	0
406	Impact of African American (AA) race on outcomes with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) Journal of Clinical Oncology, 2014, 32, e15503-e15503.	0.8	0
407	Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors Journal of Clinical Oncology, 2014, 32, TPS5101-TPS5101.	0.8	0
408	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors Journal of Clinical Oncology, 2014, 32, 4514-4514.	0.8	0
409	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors Journal of Clinical Oncology, 2014, 32, e13547-e13547.	0.8	0
410	Immunohistochemistry (IHC) to enhance the prognostic allocation of locally advanced and metastatic urothelial cancer (UC) undergoing first-line chemotherapy (CT) Journal of Clinical Oncology, 2014, 32, 4547-4547.	0.8	0
411	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE) Journal of Clinical Oncology, 2014, 32, 5047-5047.	0.8	0
412	A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2014, 32, TPS3132-TPS3132.	0.8	0
413	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors Journal of Clinical Oncology, 2014, 32, e13502-e13502.	0.8	0
414	Identification of potentially targetable kinases by concurrent high-throughput functional kinomics and RNA-sequencing (seq) of muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2014, 32, 4553-4553.	0.8	0

#	Article	IF	CITATIONS
415	The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Research, 2014, 34, 3377-82.	0.5	4
416	The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Research, 2014, 34, 3383-9.	0.5	3
417	The activity of the androgen receptor variant ARâ€V7 is regulated by FOXO1 in a PTENâ€PI3Kâ€AKTâ€dependent way. Prostate, 2013, 73, 267-277.	1.2	48
418	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal of Urology, 2013, 31, 1535-1539.	1.2	61
419	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World Journal of Urology, 2013, 31, 1211-1217.	1.2	14
420	Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. World Journal of Urology, 2013, 31, 77-82.	1.2	20
421	A new approach to second-line therapy for urothelial cancer?. Lancet Oncology, The, 2013, 14, 682-684.	5.1	8
422	Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clinical Genitourinary Cancer, 2013, 11, 423-430.	0.9	36
423	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. Journal of Translational Medicine, 2013, 11, 161.	1.8	36
424	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	0.9	47
425	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings. European Urology, 2013, 63, 58-66.	0.9	151
426	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 5-11.	1.2	39
427	The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 346-352.	0.9	21
428	Impact of Response to Prior Chemotherapy inÂPatients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications forÂTrial Design. Clinical Genitourinary Cancer, 2013, 11, 495-500.	0.9	20
429	Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1457-1463.	0.8	11
430	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 316-320.	0.9	5
431	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2013, 87, 80-89.	2.0	63
432	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	0.9	104

#	Article	IF	CITATIONS
433	Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2013, 11, 175-181.	0.9	78
434	Prognosis of renal-cell carcinoma: recognising host genetics. Lancet Oncology, The, 2013, 14, 9-10.	5.1	1
435	Critical analysis of contemporary clinical research in muscleâ€invasive and metastatic urothelial cancer. Cancer, 2013, 119, 1994-1998.	2.0	12
436	Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments. Current Urology Reports, 2013, 14, 174-183.	1.0	16
437	Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. Drugs, 2013, 73, 427-438.	4.9	95
438	A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 234-240.	0.8	2
439	Emerging drugs for urothelial carcinoma. Expert Opinion on Emerging Drugs, 2013, 18, 477-494.	1.0	8
440	Current Preclinical Models for the Advancement of Translational Bladder Cancer Research. Molecular Cancer Therapeutics, 2013, 12, 121-130.	1.9	28
441	Relationship between 6―and 9â€month progressionâ€free survival and overall survival in patients with metastatic urothelial cancer treated with firstâ€line cisplatinâ€based chemotherapy. Cancer, 2013, 119, 3020-3026.	2.0	9
442	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatinâ€based chemotherapy. Cancer, 2013, 119, 3012-3019.	2.0	82
443	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 889-897.	1.1	38
444	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage <scp>T</scp> 1 disease and negative lymph nodes after radical cystectomy. BJU International, 2013, 111, 1215-1221.	1.3	55
445	Peg-filgrastim and cabazitaxel in prostate cancer patients. Anti-Cancer Drugs, 2013, 24, 84-89.	0.7	29
446	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy Journal of Clinical Oncology, 2013, 31, 256-256.	0.8	5
447	Proportion of elderly patients with advanced bladder cancer receiving cisplatin-based chemotherapy: A large Medicare database study Journal of Clinical Oncology, 2013, 31, 276-276.	0.8	1
448	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 301-301.	0.8	2
449	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis Journal of Clinical Oncology, 2013, 31, 398-398.	0.8	4
450	Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2013, 31, 79-79.	0.8	4

#	Article	IF	CITATIONS
451	Clinical Management of Elderly Patients with Metastatic Prostate Cancer Chemotherapy. , 2013, , 179-201.		0
452	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer Journal of Clinical Oncology, 2013, 31, 251-251.	0.8	0
453	Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2013, 31, 111-111.	0.8	0
454	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials Journal of Clinical Oncology, 2013, 31, 353-353.	0.8	3
455	The preclinical anti-angiogenic and pro-apoptotic activity of lenalidomide in urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 294-294.	0.8	0
456	CEP-11981, a small molecule inhibitor of multiple angiogenic targets, in a preclinical system of urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 293-293.	0.8	0
457	Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2013, 31, 397-397.	0.8	0
458	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors Journal of Clinical Oncology, 2013, 31, 347-347.	0.8	1
459	Cisplatin-associated nephrotoxicity in clinical trials using serum creatinine (SCr) versus calculated glomerular filtration rate (GFR) as inclusion criterion: A meta-analysis Journal of Clinical Oncology, 2013, 31, 272-272.	0.8	0
460	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer Journal of Clinical Oncology, 2013, 31, 269-269.	0.8	0
461	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 4416-4426.	0.8	197
462	Objective Measures of Physical Functional Capacity Warrant Exploration to Complement or Replace the Subjective Physician Estimated Performance Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 163-166.	0.6	8
463	Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2012, 104, 1837-1840.	3.0	34
464	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2012, 30, 507-512.	0.8	168
465	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. Current Drug Targets, 2012, 13, 1676-1686.	1.0	34
466	Cisplatin and 5â€fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU International, 2012, 110, E661-6.	1.3	76
467	Clinical and pharmacokinetic evaluation of satraplatin. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 103-111.	1.5	34
468	Trends in the Use of Cytoreductive Nephrectomy in the United States. Clinical Genitourinary Cancer, 2012, 10, 159-163.	0.9	23

#	Article	IF	CITATIONS
469	Intracranial Meningeal Carcinomatosis in Metastatic Castration Resistant Prostate Cancer: Will Extension of Survival Increase the Incidence?. Clinical Genitourinary Cancer, 2012, 10, 271-273.	0.9	4
470	Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2012, 10, 239-245.	0.9	18
471	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	0.9	214
472	392 DISEASE-FREE SURVIVAL AS A SURROGATE FOR 5-YEAR OVERALL SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA. Journal of Urology, 2012, 187, .	0.2	0
473	Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 607-613.	0.8	100
474	1400 CLINICAL NODAL STAGING SCORES FOR BLADDER CANCER A NEW PREOPERATIVELY NODAL ASSESSMENT TOOL. Journal of Urology, 2012, 187, .	0.2	0
475	1904 EXTRANODAL EXTENSION IS A POWERFUL PROGNOSTIC FACTOR IN BLADDER CANCER PATIENTS WITH LYMPH NODE METASTASIS. Journal of Urology, 2012, 187, .	0.2	0
476	Novel molecular targets for the therapy of urothelial carcinoma. Expert Opinion on Therapeutic Targets, 2012, 16, 499-513.	1.5	1
477	Immunotherapy for Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 465-481.	0.8	11
478	Abiraterone acetate for metastatic prostate cancer. Lancet Oncology, The, 2012, 13, 958-959.	5.1	2
479	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treatment Reviews, 2012, 38, 919-925.	3.4	53
480	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.2	114
481	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer, 2012, 118, 5947-5954.	2.0	39
482	The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports, 2012, 14, 295-306.	1.8	38
483	Neoadjuvant Chemotherapy for Invasive Bladder Cancer. Current Urology Reports, 2012, 13, 136-146.	1.0	23
484	Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2012, 10, 6-14.	0.9	28
485	Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community. Clinical Genitourinary Cancer, 2012, 10, 1-5.	0.9	53
486	Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. European Urology, 2012, 61, 363-369.	0.9	34

#	Article	IF	CITATIONS
487	Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363–9. European Urology, 2012, 61, e4-e5.	0.9	0
488	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. European Urology, 2012, 61, 237-242.	0.9	69
489	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2012, 61, 639-647.	0.9	28
490	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology, 2012, 61, 307-316.	0.9	52
491	Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. European Urology, 2012, 61, 950-960.	0.9	69
492	Objective Evaluation of Bone Metastases in Prostate Cancer: To What End?. European Urology, 2012, 62, 85-87.	0.9	1
493	Ability of Câ€reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxelâ€based chemotherapy. BJU International, 2012, 110, E461-8.	1.3	30
494	Preoperative chemotherapy for bladder cancer. Cancer, 2012, 118, 8-11.	2.0	8
495	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy Journal of Clinical Oncology, 2012, 30, 4524-4524.	0.8	11
496	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, 4525-4525.	0.8	2
497	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era Journal of Clinical Oncology, 2012, 30, 4623-4623.	0.8	1
498	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial Journal of Clinical Oncology, 2012, 30, 4644-4644.	0.8	1
499	Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy Journal of Clinical Oncology, 2012, 30, e15003-e15003.	0.8	1
500	Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy Journal of Clinical Oncology, 2012, 30, TPS4675-TPS4675.	0.8	1
501	Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, 282-282.	0.8	6
502	Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community Journal of Clinical Oncology, 2012, 30, 285-285.	0.8	3
503	Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics Journal of Clinical Oncology, 2012, 30, 366-366.	0.8	1
504	Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2012, 30, 51-51.	0.8	1

#	Article	IF	CITATIONS
505	Prevalence and characteristics of patients with metastatic prostate cancer who receive no anticancer therapy Journal of Clinical Oncology, 2012, 30, 101-101.	0.8	0
506	Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group) Journal of Clinical Oncology, 2012, 30, 373-373.	0.8	2
507	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, 308-308.	0.8	0
508	Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC) Journal of Clinical Oncology, 2012, 30, 204-204.	0.8	0
509	The preclinical activity of lenalidomide in urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, e15002-e15002.	0.8	0
510	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC) Journal of Clinical Oncology, 2012, 30, TPS4678-TPS4678.	0.8	0
511	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis Journal of Clinical Oncology, 2012, 30, e21016-e21016.	0.8	0
512	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU International, 2011, 108, 687-692.	1.3	28
513	Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy. Journal of Urology, 2011, 185, 1216-1221.	0.2	32
514	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2011, 185, 456-461.	0.2	86
515	1847 USE OF PERIOPERATIVE CHEMOTHERAPY IN PATIENTS TREATED WITH RADICAL CYSTECTOMY AND EXTENDED LYMPH NODE DISSECTION FOR UROTHELIAL CARCINOMA OF THE BLADDER AND THE EFFECT IN DOWNSTAGING AND SURVIVAL. Journal of Urology, 2011, 185, .	0.2	0
516	Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 2011, 11, 997-1009.	1.4	20
517	Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemona¬ve castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 682-689.	0.8	53
518	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncology, The, 2011, 12, 211-214.	5.1	261
519	Contemporary management of metastatic castration-resistant prostate cancer. Current Opinion in Urology, 2011, 21, 241-247.	0.9	12
520	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2011, 60, 270-278.	0.9	53
521	The association between radiographic response and overall survival in men with metastatic castrationâ€resistant prostate cancer receiving chemotherapy. Cancer, 2011, 117, 3963-3971.	2.0	35
522	Diagnosis and Management of Urothelial Carcinoma of the Bladder. Postgraduate Medicine, 2011, 123, 43-55.	0.9	33

#	Article	IF	CITATIONS
523	Hypomethylating agents for urologic cancers. Future Oncology, 2011, 7, 447-463.	1.1	6
524	Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncology, 2011, 7, 15-24.	1.1	14
525	GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy. Clinical Cancer Research, 2011, 17, 7174-7182.	3.2	31
526	Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery. Urologia Internationalis, 2011, 87, 42-48.	0.6	19
527	Treatment of Patients With Metastatic Urothelial Cancer "Unfit―for Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2432-2438.	0.8	514
528	Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy, 2011, 11, 949-957.	1.1	9
529	Epigenetics in Prostate Cancer. Prostate Cancer, 2011, 2011, 1-12.	0.4	53
530	Neoadjuvant systemic therapy for urological malignancies. BJU International, 2010, 106, 6-22.	1.3	22
531	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Investigational New Drugs, 2010, 28, 194-198.	1.2	11
532	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. European Urology, 2010, 58, 112-117.	0.9	51
533	A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrateâ€resistant prostate cancer. Cancer, 2010, 116, 3595-3602.	2.0	20
534	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. International Journal of Urology, 2010, 17, 228-240.	0.5	8
535	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. OncoTargets and Therapy, 2010, 3, 147.	1.0	14
536	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncology, 2010, 6, 665-679.	1.1	26
537	First-Line Systemic Therapy Trials for Advanced Transitional-Cell Carcinoma of the Urothelium: Should We Stop Separating Cisplatin-Eligible and -Ineligible Patients?. Journal of Clinical Oncology, 2010, 28, e441-e442.	0.8	19
538	Suggestions for Regulatory Agency Approval of Second-Line Systemic Therapy for Metastatic Transitional Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, e205-e207.	0.8	8
539	Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. Expert Review of Anticancer Therapy, 2010, 10, 439-450.	1.1	6
540	Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling. Molecular Cancer Therapeutics, 2010, 9, 1128-1135.	1.9	28

#	Article	IF	CITATIONS
541	1032 VALIDATION OF RESIDUAL PATHOLOGIC STAGE AT RADICAL CYSTECTOMY AS A PROGNOSTIC FACTOR IN PATIENTS WITH CT2N0 BLADDER CANCER. Journal of Urology, 2010, 183, .	0.2	0
542	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. Journal of Urology, 2010, 184, 888-894.	0.2	64
543	pT3 Substaging is a Prognostic Indicator for Lymph Node Negative Urothelial Carcinoma of the Bladder. Journal of Urology, 2010, 184, 470-474.	0.2	29
544	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncology, The, 2010, 11, 861-870.	5.1	123
545	Abstract LB-80: Correlation of serum cytokines with clinical responses in patients treated with BPX-101, a novel dendritic cell vaccine for metastatic castration resistant prostate cancer (mCRPC). , 2010, , .		0
546	Emerging vaccine therapy approaches for prostate cancer. Reviews in Urology, 2010, 12, 25-34.	0.9	11
547	Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Molecular Cancer Therapeutics, 2009, 8, 1772-1778.	1.9	14
548	Review: Novel agents for advanced bladder cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 37-50.	1.4	0
549	Satraplatin for the therapy of castration-resistant prostate cancer. Future Oncology, 2009, 5, 931-940.	1.1	7
550	Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer, 2009, 115, 4104-4109.	2.0	171
551	Everolimus for renal cell carcinoma: predictive factors for response and future directions. Medical Oncology, 2009, 26, 46-53.	1.2	0
552	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. Update on Cancer Therapeutics, 2009, 3, 133-145.	0.9	2
553	Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 391-399.	0.8	69
554	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. Journal of Urology, 2009, 182, 459-465.	0.2	15
555	Patient Selection for Phase II Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 216-219.	0.6	7
556	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 2008, 112, 2519-2519.	2.0	0
557	Neoadjuvant therapy as a paradigm to develop systemic cancer therapy. Drug Development Research, 2008, 69, 388-397.	1.4	0
558	Axitinib for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 741-748.	1.9	60

#	Article	IF	CITATIONS
559	Novel agents for muscleâ€invasive and advanced urothelial cancer. BJU International, 2008, 101, 937-943.	1.3	11
560	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU International, 2008, 102, 1354-1360.	1.3	15
561	Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy. Clinical Genitourinary Cancer, 2008, 6, 134-137.	0.9	9
562	Novel Antiangiogenic Agents in the Treatment of Refractory Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2008, 6, S29-S36.	0.9	4
563	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 253-261.	1.9	84
564	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 1885-1893.	0.9	3
565	Trial Design for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 3647-3648.	0.8	2
566	Current optimal chemotherapy for advanced urothelial cancer. Expert Review of Anticancer Therapy, 2008, 8, 51-61.	1.1	5
567	Recent advances in the therapy of renal cancer. Expert Opinion on Biological Therapy, 2007, 7, 233-242.	1.4	8
568	Lapatinib plus Capecitabine in Breast Cancer. New England Journal of Medicine, 2007, 356, 1471-1472.	13.9	8
569	Management of Recurrent Testicular Germ Cell Tumors. Oncologist, 2007, 12, 51-61.	1.9	29
570	Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma. Urology, 2007, 69, 1221-1226.	0.5	56
571	Vaccine therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 451-459.	0.8	9
572	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 2007, 110, 2628-2639.	2.0	18
573	Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy. Clinical Genitourinary Cancer, 2007, 5, 457-459.	0.9	11
574	Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Current Oncology Reports, 2007, 9, 115-119.	1.8	191
575	Neoadjuvant chemotherapy for bladder cancer. Oncology, 2007, 21, 1673-81; discussion 1686-8, 1691, 1694.	0.4	3
576	Targeting Growth Factor and Antiangiogenic Pathways in Clear-Cell Renal Cell Carcinoma: Rationale and Ongoing Trials. Clinical Genitourinary Cancer, 2006, 5, S31-S39.	0.9	5

#	Article	IF	CITATIONS
577	Hormone refractory prostate cancer: Management and advances. Cancer Treatment Reviews, 2006, 32, 90-100.	3.4	31
578	New Approaches in Hormone Refractory Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 196-201.	0.6	13
579	Bladder cancer update. Postgraduate Medicine, 2006, 119, 30-37.	0.9	0
580	Perioperative chemotherapy for bladder cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 133-144.	2.0	21
581	Systemic Chemotherapy for Urothelial Cancer. Clinical Genitourinary Cancer, 2006, 5, 34-42.	0.9	1
582	Expression of estrogen receptors-α and -β in bladder cancer cell lines and human bladder tumor tissue. Cancer, 2006, 106, 2610-2616.	2.0	182
583	Problems With the Randomized Discontinuation Design. Journal of Clinical Oncology, 2006, 24, 4669a-4670.	0.8	5
584	Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly. Journal of Clinical Oncology, 2005, 23, 4459-4460.	0.8	8
585	Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly. Journal of Clinical Oncology, 2005, 23, 4458-4459.	0.8	0
586	PSA and Clinical Responses to Celecoxib in a Patient With Prostate Cancer and Bone Metastases. Mayo Clinic Proceedings, 2005, 80, 1100-1101.	1.4	2
587	Communicating the Value of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2003, 21, 948-949.	0.8	7
588	Bevacizumab in Renal-Cell Cancer. New England Journal of Medicine, 2003, 349, 1674-1674.	13.9	9
589	What to do when you discover testicular cancer. Postgraduate Medicine, 1999, 105, 229-236.	0.9	5
590	Emerging Therapies in Penile Cancer. Frontiers in Oncology, 0, 12, .	1.3	1